Anti-Human CD279 (PD-1) (Nivolumab)

Antibody Details

Product Details

Reactivity Species

Human/Cynomolgus Monkey

Host Species

Human

Expression Host

HEK-293

FC Effector Activity

Active

Immunogen

Human PD-1

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

Formulation

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Regulatory Status

Research Use Only (RUO). Non-Therapeutic.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRID

AB_2893893

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for Nivolumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

IHC
FA
FC
B

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Nivolumab. Clone 5C4.B8 binds to the extracellular portion of Human/Cynomolgus PD-1 and does not bind to other IgG superfamily proteins. This product is for research use only.

Antigen Distribution

PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.

Background

Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.¹ PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.² Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.³ Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.⁴ This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.

Antigen Details

Protein

PD-1

Ligand/Receptor

PD-L1 and PD-L2

PubMed

PD-1

NCBI Gene Bank ID

5133

UniProt.org

Information on Uniprot.org

Research Area

Costimulatory Molecules

.

Immuno-Oncology

.

Immunology

References & Citations

1. Minato, N. et al. (2002) Proc Natl Acad Sci U S A. 99(19): 12293–97.

2. Korman, AJ. et al. (2014) Cancer Immunol Res. 2(9):846-56.

3. Li, Y. et al. (2016) MAbs. 8(5):951-60.

4. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33.

Technical Protocols